290 related articles for article (PubMed ID: 33407601)
21. Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study.
Jiang Y; Zhao J; Zhang Y; Li K; Li T; Chen X; Zhao S; Zhao S; Liu K; Dong Z
J Transl Med; 2018 May; 16(1):138. PubMed ID: 29788985
[TBL] [Abstract][Full Text] [Related]
22. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
23. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
Fumagalli D; Wilson TR; Salgado R; Lu X; Yu J; O'Brien C; Walter K; Huw LY; Criscitiello C; Laios I; Jose V; Brown DN; Rothé F; Maetens M; Zardavas D; Savas P; Larsimont D; Piccart-Gebhart MJ; Michiels S; Lackner MR; Sotiriou C; Loi S
Ann Oncol; 2016 Oct; 27(10):1860-6. PubMed ID: 27672107
[TBL] [Abstract][Full Text] [Related]
24. Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.
Cheng S; Nguyen ET; Pagano I; Fukui JA
Oncol Res Treat; 2023; 46(1-2):26-32. PubMed ID: 36481616
[TBL] [Abstract][Full Text] [Related]
25. Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
Niwa Y; Asano M; Nakagawa T; France D; Semba T; Funahashi Y
Anticancer Res; 2020 Dec; 40(12):6699-6712. PubMed ID: 33288563
[TBL] [Abstract][Full Text] [Related]
26. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
27. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.
Chen Z; Huang W; Tian T; Zang W; Wang J; Liu Z; Li Z; Lai Y; Jiang Z; Gao J; Shen L
J Hematol Oncol; 2018 Feb; 11(1):20. PubMed ID: 29433585
[TBL] [Abstract][Full Text] [Related]
28. Patient-Derived Xenograft Models in Breast Cancer Research.
Na D; Moon HG
Adv Exp Med Biol; 2021; 1187():283-301. PubMed ID: 33983584
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
30. Validity of patient-derived xenograft mouse models for lung cancer based on exome sequencing data.
Kim J; Rhee H; Kim J; Lee S
Genomics Inform; 2020 Mar; 18(1):e3. PubMed ID: 32224836
[TBL] [Abstract][Full Text] [Related]
31. Separation of breast cancer and organ microenvironment transcriptomes in metastases.
Alzubi MA; Turner TH; Olex AL; Sohal SS; Tobin NP; Recio SG; Bergh J; Hatschek T; Parker JS; Sartorius CA; Perou CM; Dozmorov MG; Harrell JC
Breast Cancer Res; 2019 Mar; 21(1):36. PubMed ID: 30841919
[TBL] [Abstract][Full Text] [Related]
32. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
33. Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy.
Kohli M; Wang L; Xie F; Sicotte H; Yin P; Dehm SM; Hart SN; Vedell PT; Barman P; Qin R; Mahoney DW; Carlson RE; Eckel-Passow JE; Atwell TD; Eiken PW; McMenomy BP; Wieben ED; Jha G; Jimenez RE; Weinshilboum R; Wang L
PLoS One; 2015; 10(12):e0145176. PubMed ID: 26695660
[TBL] [Abstract][Full Text] [Related]
34. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.
Drapkin BJ; George J; Christensen CL; Mino-Kenudson M; Dries R; Sundaresan T; Phat S; Myers DT; Zhong J; Igo P; Hazar-Rethinam MH; Licausi JA; Gomez-Caraballo M; Kem M; Jani KN; Azimi R; Abedpour N; Menon R; Lakis S; Heist RS; Büttner R; Haas S; Sequist LV; Shaw AT; Wong KK; Hata AN; Toner M; Maheswaran S; Haber DA; Peifer M; Dyson N; Thomas RK; Farago AF
Cancer Discov; 2018 May; 8(5):600-615. PubMed ID: 29483136
[TBL] [Abstract][Full Text] [Related]
35. Comparative genomic analysis of primary tumors and metastases in breast cancer.
Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
[TBL] [Abstract][Full Text] [Related]
36. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
[TBL] [Abstract][Full Text] [Related]
37. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
[No Abstract] [Full Text] [Related]
38. Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
Barroso-Sousa R; Jain E; Cohen O; Kim D; Buendia-Buendia J; Winer E; Lin N; Tolaney SM; Wagle N
Ann Oncol; 2020 Mar; 31(3):387-394. PubMed ID: 32067680
[TBL] [Abstract][Full Text] [Related]
39. Genomic characterization of metastatic breast cancers.
Bertucci F; Ng CKY; Patsouris A; Droin N; Piscuoglio S; Carbuccia N; Soria JC; Dien AT; Adnani Y; Kamal M; Garnier S; Meurice G; Jimenez M; Dogan S; Verret B; Chaffanet M; Bachelot T; Campone M; Lefeuvre C; Bonnefoi H; Dalenc F; Jacquet A; De Filippo MR; Babbar N; Birnbaum D; Filleron T; Le Tourneau C; André F
Nature; 2019 May; 569(7757):560-564. PubMed ID: 31118521
[TBL] [Abstract][Full Text] [Related]
40. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
